Tag: NAL



Nuheara Receives FDA Clearance for HP Hearing PRO

Following the OTC hearing aid law going into effect on October 17, 2022 in the US, Nuheara plans to bring to market its first medical device as the HP Hearing PRO under its worldwide Trademark License Agreement for use of HP trademarks on Nuheara’s hearing aids, personal sound amplification devices, and accessories.

Meeting the Challenges of OTC: Who Are Self-fitting Hearing Aids Really For?

What personal and technological factors will influence consumers’ success with self-fitting OTC hearing devices? Researcher Elizabeth Convery, PhD, looks at recent studies suggesting that OTC manufacturers and providers must address a range of important personal and device factors before self-fitting can become a viable option for adults with hearing loss.

Read More

The Impact of Unilateral Hearing Loss on Adult Life

There is a need to improve awareness and to better understand the impact and struggles of people who have unilateral hearing loss (UHL), the professionals who treat them, and those who work, live, and socialize with them. With better awareness comes better understanding, so health professionals can refer them rather than dismiss them. Moreover, better understanding can fuel motivation and allow the person with UHL to be more proactive about managing the condition while reducing anxiety.

Read More

NAL, CAEPs, OTC Hearing Aids, and More: An Interview with Brent Edwards, PhD

Brent Edwards, PhD, who has recently been appointed director of the National Acoustic Laboratories (NAL) research center in Sydney, Australia, is interviewed by Douglas Beck, AuD, in this edition of “HR’s“ Inside the Research. Topics include research at NAL, the NAL’s cortical auditory evoked potential (CAEP) system known as HEARLab, over-the-counter hearing aids, and more.

Read More

Effects of Amplification on Cortical Electrophysiological Function

There has been great interest in using speech-evoked cortical auditory evoked potentials (CAEP) as an objective hearing aid validation measure, because CAEPs allow us to assess the audibility of speech sounds at the highest (cortical) levels. Here is a review by Sridhar Krishnamurti and Larry Wise, as well as results from a study they conducted that suggests there is clinical value of CAEPs for assessing cortical changes from amplification, as well as using this data in audiology services to demonstrate patient benefit.

Read More

Multi-center Evidence of Reduced Listening Effort Using New Hearing Aid Technology

This review of clinical studies from three leading hearing aid research centers shows a consistent trend for the Signia primax features to significantly reduce listening effort. Moreover, research from one site revealed that speech recognition performance for hearing-impaired listeners (pure-tone average 35-60 dB) using the primax Narrow Directionality algorithm was equal to that of normal-hearing individuals for the same speech-in-noise task.

Read More